Two open-label trials established the efficacy of<unk>  (with or without dexamethasone) on days 1,4,8, and 11 of a 21-day cycle for a maximum of eight cycles in heavily pretreated people with relapsed/refractory multiple myeloma. The phase III demonstrated the superiority of<unk>  over a high-dose dexamethasone regimen (e.g. median TTP 6.2 vs 3.5 months, and 1-year survival 80% vs 66%). New studies show that<unk>  may potentially help recover from vincristine treatment in treating acute lymphoblastic leukemia, when replacing vincristine in the process.<unk>  was also evaluated together with other drugs for the treatment of multiple myelomas in adults. It was seen that<unk>  plus lenalidomide plus dexamethasone as well as<unk>  plus melphalan and prednisone may result in a large increase in the progression-free survival.
Bortezomib
Lenalidomide
Ixazomib
Vincristine
Pomalidomide
Ifosfamide
Rituximab
Carfilzomib